Injection occurs 30-60 minutes before sleep, 3-5 times per week
Researchers working with reconstitution should also reference our peptide reconstitution guide
Its most well-known iteration, CJC-1295 DAC, was developed by the Canadian biotech company ConjuChem Technologies in the mid-2000s [1]
it becomes part of a broader skincare system that addresses hydration, repair, and long-term skin resilience
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Localized erythema (injection site) Transient hyperpigmentation (topical, in some users) Rare contact dermatitis Known interactions Vitamin C (theoretical copper-ascorbate redox cycling) Retinoids (may potentiate irritation when stacked topically) Contraindications Wilson's disease (copper-accumulation disorder) Active malignancy at the local site (theoretical, due to angiogenic activity) REGULATORY STATUS FDA Topical GHK-Cu formulations are marketed as cosmetic ingredients under FDA cosmetic regulation (cosmetics generally do not require FDA premarket approval)
The integrated experience is what distinguishes PSPeptides